GUIDANT REVEALS RESULTS OF CLINICAL TRIAL ABSORB

Guidant Corporation revealed results of clinical trial designed to evaluate the safety of a fully bioabsorbable everolimus eluting stent platform for the treatment of coronary artery disease.
Trading Markets